Syndax Pharmaceuticals (SNDX) EBITDA (2015 - 2026)

Syndax Pharmaceuticals' EBITDA history runs 12 years deep, the most recent figure standing at -$34.2 million for Q1 2026.

• In Q1 2026, EBITDA rose 59.17% year-over-year to -$34.2 million; the TTM figure through Mar 2026 stood at -$223.5 million (up 35.0% YoY), while the FY2025 annual figure was -$273.1 million, up 19.6% from the prior year.
• EBITDA for Q1 2026 stood at -$34.2 million, up from -$62.5 million in the prior quarter.
• The five-year high for EBITDA was -$34.2 million in Q1 2026, with the low at -$96.4 million in Q4 2024.
• The 5-year median for EBITDA is -$57.4 million (2025), against an average of -$60.5 million.
• The sharpest annual moves came in 2022 and 2026: EBITDA sank 143.9% in 2022, then jumped 59.17% in 2026.
• Syndax Pharmaceuticals' EBITDA stood at -$42.0 million in 2022, then tumbled by 85.34% to -$77.9 million in 2023, then slipped by 23.7% to -$96.4 million in 2024, then soared by 35.09% to -$62.5 million in 2025, then surged by 45.32% to -$34.2 million in 2026.
• Business Quant data shows SNDX's EBITDA at -$34.2 million in Q1 2026, -$62.5 million in Q4 2025, and -$57.4 million in Q3 2025.